Healius Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Paul Anderson

Chief executive officer

AU$234.6k

Total compensation

CEO salary percentage	82.5%
CEO tenure	1.2yrs
CEO ownership	n/a
Management average tenure	1.3yrs
Board average tenure	1.7yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Paul Anderson's remuneration changed compared to Healius's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	n/a	n/a	-AU$984m
Sep 30 2023	n/a	n/a	-AU$682m
Jun 30 2023	AU$235k	AU$194k	-AU$380m

Compensation vs Market: Paul's total compensation ($USD153.32K) is below average for companies of similar size in the Australian market ($USD764.35K).

Compensation vs Earnings: Insufficient data to compare Paul's compensation with company performance.

CEO

Paul Anderson

1.2yrs

Tenure

AU$234,618

Compensation

Mr. Paul D. Anderson serves as Managing Director, Chief Executive Officer since 2024 at Healius Limited and has been Group Chief Financial Officer of Healius Limited since March 1, 2023 and also served as...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Paul Anderson	MD, Group CFO	1.2yrs	AU$234.62k	no data
John McKechnie	Advisor	4.8yrs	AU$275.71k	0.028% A$ 230.9k
Jan Van Rooyen	Head & Group Executive of Healius Pathology	less than a year	AU$20.68k	no data
Phil Lucas	Chief Executive of Lumus Imaging	1.3yrs	no data	no data
Ian Mcphan	Chief Operating Officer of Healius Pathology	no data	no data	no data
Sharon Ng	Head of Group FP&A	no data	no data	no data
Mary Weaver	Company Secretary	1.2yrs	no data	no data
John Houston	Advisor	no data	AU$1.16m	no data

1.3yrs

Average Tenure

Experienced Management: HLS's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Paul Anderson	MD, Group CFO	less than a year	AU$234.62k	no data
Gordon Davis	Non-executive Director	8.8yrs	AU$181.72k	0.017% A$ 140.6k
Kathryn McKenzie	Interim Non-Executive Independent Chair	3.3yrs	AU$170.70k	0.014% A$ 115.1k
Michael Stanford	Independent Non-Executive Director	less than a year	no data	0.0045% A$ 37.3k
Ravi Jeyaraj	Director	less than a year	no data	no data
Sally Evans	Independent Non-Executive Director	5.8yrs	AU$176.25k	0.011% A$ 92.0k
John Mattick	Non Executive & Independent Director	2.2yrs	AU$157.74k	0.0075% A$ 62.5k
Charlie Taylor	Independent Non-Executive Director	1.2yrs	AU$42.07k	0.016% A$ 133.9k

1.7yrs

Average Tenure

63.5yo

Average Age

Experienced Board: HLS's board of directors are not considered experienced ( 1.7 years average tenure), which suggests a new board.

Healius Management

Management criteria checks 1/4

Key information

Recent management updates

High number of new directors

Interim Non-Executive Independent Chair recently bought AU$81k worth of stock

High number of new directors

Healius Limited Appoints Ravi Jeyaraj as Director

Healius Limited Announces Chair Changes

Healius Limited Announces Chair Changes

Recent updates

High number of new directors

Healius Limited to Report First Half, 2024 Results on Feb 27, 2024

Australian Clinical Labs Limited (ASX:ACL) cancelled the acquisition of Healius Limited (ASX:HLS) from Tanarra Capital Australia Pty Ltd, Perpetual Investment Management Ltd and others.

New minor risk - Shareholder dilution

Interim Non-Executive Independent Chair recently bought AU$81k worth of stock

High number of new directors

Healius Limited Appoints Ravi Jeyaraj as Director

Healius Limited Announces Chair Changes

Healius Limited Announces Chair Changes

Healius Limited has filed a Follow-on Equity Offering in the amount of AUD 187.32 million.

Healius Limited has filed a Follow-on Equity Offering in the amount of AUD 187.32 million.

Healius Limited, Annual General Meeting, Nov 01, 2023

Australian Clinical Labs Limited (ASX:ACL) canceled the acquisition of Healius Limited (ASX:HLS)

Healius Limited Appoints Michael Stanford as Director

Full year 2023 earnings released

Healius Limited to Report Fiscal Year 2023 Results on Aug 30, 2023

Healius Limited Appoints Jan Van Rooyen as Group Executive, Healius Pathology Effective 1 June 2023

High number of new directors

Independent Non Executive Chairman recently bought AU$103k worth of stock

First half 2023 earnings released: AU$0.045 loss per share (vs AU$0.40 profit in 1H 2022)

Healius Limited Announces Resignation of Alison Stephenson as Company Secretary

Healius Limited to Report First Half, 2023 Results on Feb 27, 2023

Nexus Hospitals entered into an agreement to acquire Montserrat Healthcare Pty Ltd from Healius Limited (ASX:HLS).

QIC Reportedly Set to Clinch Healius Day Hospital Unit for $140 Million Plus

MD, CEO & Director recently sold AU$660k worth of stock

Brookfield Reportedly Drops Out of Race to Buy Healius

Independent Non Executive Director recently bought AU$86k worth of stock

Non Executive & Independent Director recently bought AU$70k worth of stock

Full year 2022 earnings released: EPS: AU$0.50 (vs AU$0.11 in FY 2021)

Healius Limited Announces Fully Franked Ordinary Paid Dividend for the Six Months Ended June 30, 2022, Payable on September 21, 2022

Healius Limited, Annual General Meeting, Oct 20, 2022

Healius Reportedly Launches Day Surgery Sale Process

Healius Reportedly Keeps Watching Brief on Integral Diagnostics

Healius Limited to Report Fiscal Year 2022 Results on Aug 31, 2022

Healius Reportedly Seeks X-Ray Factor in Day Surgeries Sale Plan

Healius Limited Announces Appointment of John Mattick as Non-Executive Director

Upcoming dividend of AU$0.10 per share

First half 2022 earnings: EPS in line with expectations, revenues disappoint

Healius Limited Announces Ordinary Fully Paid Dividend for the Period of Six Months December 31, 2021, Payable April 15, 2022

Healius Limited to Report First Half, 2022 Results on Feb 23, 2022

Healius Limited (ASX:HLS) acquired Agilex Biolabs Pty Ltd.

Healius Limited (ASX:HLS) entered into an agreement to acquire Agilex Biolabs Pty Ltd for approximately AUD 300 million.

MD, CEO & Director recently sold AU$713k worth of stock

Upcoming dividend of AU$0.068 per share

Full year 2021 earnings released: EPS AU$0.11 (vs AU$0.12 in FY 2020)

Healius Limited (ASX:HLS) acquired Axis Diagnostic Holdings Pty Limited.

Healius Reportedly to Sale Day Surgeries

Healius Limited Decides Not to Provide Earnings Guidance for the Second Half of 2021

Healius Limited Appoints Kate McKenzie as A Non-Executive Director Effective from 25 February 2021

New 90-day high: AU$4.16

Healius Limited(ASX:HLS) dropped from S&P/ASX 100 Index

New 90-day high: AU$3.90

BGH Capital completed the acqusition of Primary Care Business of Healius Ltd from Healius Limited (ASX:HLS) for AUD485 million.

Independent Non Executive Director recently bought AU$53k worth of stock

New 90-day high: AU$3.77

Healius Limited Announces Retirement of Arlene Tansey as Non-Executive Director

New 90-day high: AU$3.46

Healius Limited to Report Fiscal Year 2021 Results on Aug 20, 2021

Full year earnings released - EPS AU$0.12

New 90-day high - AU$3.40

Earnings released

New 90-day high - AU$3.20

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Board Members